Nestl茅 (NESN) Receives Average Rating of “Hold” from Analysts

Shares of Nestl茅 (VTX:NESN) have received an average rating of “Hold” from the twenty-one brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is CHF 86.28.

NESN has been the topic of several research reports. Sanford C. Bernstein set a CHF 81 price objective on shares of Nestl茅 and gave the company a “neutral” rating in a research report on Monday, May 7th. JPMorgan Chase & Co. set a CHF 95 price objective on shares of Nestl茅 and gave the company a “buy” rating in a research report on Tuesday, June 19th. BNP Paribas set a CHF 78 price objective on shares of Nestl茅 and gave the company a “sell” rating in a research report on Monday. Baader Bank set a CHF 86 price objective on shares of Nestl茅 and gave the company a “buy” rating in a research report on Monday, May 7th. Finally, Barclays set a CHF 83 price objective on shares of Nestl茅 and gave the company a “neutral” rating in a research report on Tuesday, May 8th.

Shares of Nestl茅 traded up CHF 0.06, hitting CHF 76.50, on Monday, MarketBeat reports. The stock had a trading volume of 15,650,000 shares, compared to its average volume of 6,940,000. Nestl茅 has a twelve month low of CHF 73.34 and a twelve month high of CHF 86.40.

Nestl茅 Company Profile

Nestle SA is a nutrition, health and wellness company. The Company’s segments are Zone Europe, Middle East and North Africa (EMENA); Zone Americas (AMS); Zone Asia, Oceania and sub-Saharan Africa (AOA); Nestle Waters; Nestle Nutrition, and Other Businesses. The Company operates in the United States, Greater China Region, Switzerland and Rest of the World.

Syros Pharmaceuticals (SYRS) Trading 5.4% Higher

Syros Pharmaceuticals (NASDAQ:SYRS) shares traded up 5.4% during mid-day trading on Friday . The company traded as high as $11.26 and last traded at $11.10. 1,391,833 shares traded hands during mid-day trading, an increase of 505% from the average session volume of 229,979 shares. The stock had previously closed at $10.53.

A number of research analysts recently issued reports on the stock. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 6th. BidaskClub raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 22nd. Wedbush reissued an “outperform” rating and issued a $13.00 price objective (up from $11.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, March 13th. Zacks Investment Research cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. Finally, HC Wainwright reissued a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, March 14th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.13.

Get Syros Pharmaceuticals alerts:

The company has a market capitalization of $416.35 million, a price-to-earnings ratio of -5.21 and a beta of -2.69.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, May 10th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.14). The business had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $3.41 million. analysts expect that Syros Pharmaceuticals will post -2.2 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of SYRS. Two Sigma Advisers LP bought a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth $105,000. Adalta Capital Management LLC bought a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth $111,000. The Manufacturers Life Insurance Company grew its stake in shares of Syros Pharmaceuticals by 299.9% during the first quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock worth $168,000 after buying an additional 9,691 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth $191,000. Finally, Two Sigma Investments LP grew its stake in shares of Syros Pharmaceuticals by 80.3% during the fourth quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock worth $206,000 after buying an additional 9,439 shares during the last quarter. 56.84% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.